Ras proteins play a central role in control of cell proliferation, differentiation, and other cellular functions (1) . They function by cycling between inactive GDP-bound and active GTPbound forms. This molecular switch is mainly regulated by guanine nucleotide exchange factor that catalyzes an exchange of GDP for GTP and by GTPase-activating protein that activates the intrinsic GTPase activity of Ras and thus converts Ras-GTP to GDP. Loss of GTPase activity due to mutations of Ras, frequently found in human cancers, contributes to cell transformation, tumor malignancy and metastasis (2) (3) (4) (5) .
Ras can be activated by a great number of extracellular ligands that bind to transmembrane receptors. The active GTPbound Ras signals to downstream effectors through direct interactions (6, 7) . The Raf kinase family is a downstream effector of Ras and is best known as an essential component in mediating proliferative signals (8, 9) . Raf is activated at the plasma membrane through binding to the membrane-associated Ras-GTP and by additional modifications such as phosphorylation. The active Raf then triggers sequential activation of MEK 1 and MAPK. The activated MAPK in turn phosphorylates a variety of intracellular substrates including such transcription factors as Myc, AP1, and Elk1, necessary for cell growth. On many occasions, Ras signals diverge to the Rho GTPase family, which elicits cytoskeletal changes also required for cell growth (10 -12) . Joneson et al. (12) have elaborated distinct roles of two residues in the Ras effector domain critical for the activation of Raf and Rac. Mutating either of them causes loss of Ras ability to induce DNA synthesis. Mutation of one interferes with Ras activation of Raf, and mutation of the other abolishes Ras induction of membrane ruffling. The full function of Ras can be restored by introducing both mutants into cells. Furthermore, active mutants of Raf and Rac cooperate to induce transformation of fibroblast cells (10) .
The p21-activated kinases (Paks), mammalian homologues of Ste20-like Ser/Thr protein kinases, are direct targets of Rac and Cdc42 GTPases (13) . The Pak family consists of at least six members (Pak1 to 6), among which Pak1 to 3 are well characterized (13) (14) (15) . Members of the Pak family have been implicated in a variety of intracellular signaling events, including cell proliferation, apoptosis, cell cycle progression, stress response, production of oxidative species, cell adhesion, and motility. These regulatory processes are accomplished mostly through kinase-dependent but some through kinase-independent mechanisms. Pak is composed of an amino-terminal regulatory region and a carboxyl-terminal kinase domain. The amino-terminal moiety of Pak1 to 3 inhibits the catalytic domain by direct interaction. Activation of Pak requires binding of GTP-bound Cdc42 or Rac to the amino-terminal p21-binding domain (PBD) so as to disrupt the inhibitory interaction between the amino-terminal domain and the kinase domain. As a result, Pak undergoes autophosphorylation to secure an active conformation (16 -18) . In addition, Pak is reported to be activated by a GTPase-independent mechanism, such as by sphingosine (19) or protein kinase B/AKT (20) .
Many lines of evidence have demonstrated that members of the Pak family act as molecular linkers that couple signaling events between Ras and the Rho GTPase family (21) (22) (23) (24) (25) (26) (27) (28) . For example, Pak1 mediates V12Ras-induced cell transformation (21, 22) and cooperates with Raf-1 by phosphorylating MEK1, leading to maximal activation of MEK and MAPK (23) . King et al. (24) first identified Pak2 (␥Pak) as a Raf Ser 338 kinase important for Raf activation. Pak1 and 2 have also been shown to be necessary for the activation of Raf-1 by V12Ras (24) , an active mutant of phosphatidylinositol 3-kinase (25) , and integrin (26) . We have recently linked Pak to a signal originating in changes in microtubule dynamics by showing that nocodazole activates Pak and consequently causes Raf Ser 338 phosphorylation and activation (27) . A recent study by Li et al. (28) has also positioned Rac/Cdc42 and Pak in the V12Ras-induced Raf activation pathway.
Although an increasing number of studies support that Rac/Cdc42-regulated Pak phosphorylates Raf Ser 338 during Raf activation, a recent report does not agree with this notion (29) . To further clarify whether Pak is a physiological kinase phosphorylating Raf, the present study attempts to examine the direct interaction between Raf and Pak. Here, we show that Raf-1 interacts with Pak1 under both physiological and overexpressed conditions. The association is closely related to the activation state of Pak1, since it is significantly stimulated by such agents as 4␤-12-O-tetradecanoylphorbol-13-acetate (TPA) and nocodazole and overexpression of active mutants of Rac (V12Rac) and Ras (V12Ras). In addition, the carboxyl-terminal kinase domain of Pak1 showed much stronger binding to Raf than the full-length Pak1, whereas the kinase-dead mutant Pak hardly bound to Raf-1. Furthermore, the binding site for Raf-1 was mapped to the carboxyl kinase domain of Pak1.
EXPERIMENTAL PROCEDURES
Materials-Nocodazole and TPA, and anti-FLAG monoclonal antibody (M2) were purchased from Sigma. GSH-Sepharose 4B was from Amersham Biosciences. Monoclonal antibodies against Raf-1 (E10) and GST (B14); polyclonal antibodies against Raf-1 (C12), Pak1(N20) and MEKK1(C22); Raf-1 (E10) and Pak1 blocking peptides; horseradish peroxidase-conjugated second antibodies; and protein A/G-agarose were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rat monoclonal antibody against Raf phospho-Ser 338 was from Upstate Biotechnology, Inc. (Lake Placid, NY). Polyclonal antibodies against MAPK (Erk1/2) and phospho-MAPK (Erk1/2) were from Cell Signaling. Anti-Myc (9E10) antibody was used as previously described (27) .
DNA Construction-cDNAs encoding Raf-1 were constructed into pMT2Myc and pCMV5Flag plasmids (27) . cDNAs for wild type Raf, kinase domain (BXBRaf), 14-3-3, and KiRas (V12) were inserted into pEBG (27) . Pak cDNAs for wild type, active mutant (T423E), and kinase-dead (K299A) were inserted into pEBG or pCDNA3 in which a Myc epitope was engineered at the amino terminus of Pak1. V12Rac was in pCMV5Flag plasmid (27) .
For deletion mutations of Pak1, pairs of primers were synthesized, and cDNAs for Pak variants were amplified by polymerase chain reaction with Pfu polymerase and inserted into pEBG or pCDNA3.1Myc (for ⌬C and ⌬N only). The primers are as follows: ⌬C (aa 1-247), up: 5Ј-AGCTTTGAATTC(EcoRI) ATGTCAAATAACGGCCTAGAC-3Ј, down: 5Ј-AGCTCTCGAGCGGCCGC(NotI)TATTTAGGCTTCTTCTTC-TGCTT-3Ј; ⌬N (aa 248 -545), up: 5Ј-AGCTTTGGATCC(BamHI)ATGT-CTGATGAGGAGATCTTG-3Ј, down: 5Ј-AGCTCTCGAGCGGCCGCTT-TTAGTGATTGTTCTTTGTTGCC-3Ј; P1 (aa 347-545), up: 5Ј-AGCTTT-GGATCCTTGGCTGGAGGCTCCTTGACA-3Ј, down: same as ⌬N; P2 (aa 464 -545), up: 5Ј-AGCTTTGGATCCCTCAATGAAAACCCTCTGAG-A-3Ј, down: same as ⌬N; P3 (aa 248 -346), up: same as ⌬N, down: 5Ј-AGCTCTCGAGCGGCCGCTAGTATTCCATAACAACCCACAG-3Ј; P4 (aa 248 -463), up: same as ⌬N, down: 5Ј-AGCTCTCGAGCGGCCG-CTAGTATGGAGGCTCCCCTTCAAT-3Ј.
Transfections, Immunoprecipitation, and Western Blot-Human embryonic kidney 293 cells (HEK293T) or COS7 cells as indicated were used in this study. They were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. A day before transfection, 293T cells were split onto 100-mm plates to allow them to reach 50 -70% confluence the next day and transfected with plasmid cDNA using the calcium phosphate precipitation method (27) . COS7 cells were transfected using LipofectAMINE reagents (Invitrogen). Forty-eight hours post-transfection, cells were serum-starved in Dulbecco's modified Eagle's medium containing 0.1% fetal bovine serum for 16 -20 h and treated with or without TPA or nocadazole, as indicated in the figure legends (Fig. 3A , 5B).
Cells were lysed in a lysis buffer (20 mM Tris-HCl, pH 7.8, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , and 25 mM ␤-glycerol phosphate, 1 mM dithiothreitol, 1% Nonidet P-40 and protease inhibitors and centrifuged at 14,000 ϫ g for 15 min at 4°C. Supernatants were assayed for protein concentrations using the Bio-Rad Protein Assay kit.
For immunoprecipitation, cell lysates containing recombinant proteins were incubated with specific antibodies and protein A/G-Sepharose beads at 4°C overnight. The precipitates were washed three times with ice-cold lysis buffer and twice with kinase buffer (25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 5 mM MgCl 2 , 1 mM dithiothreitol) for kinase assay. For purification of recombinant GST fusion proteins, GSH-Sepharose was incubated with lysates and washed as immunoprecipitation. The precipitates were then analyzed by Western blot.
For Western blotting, proteins from 10 -50 g of cell extracts were separated by 8% SDS-polyacrylamide gel electrophoreses (SDS-PAGE) and electrophoretically transferred to polyvinylidene difluoride membranes (Millipore Corp.) in a transfer buffer consisting of 154 mM glycine, 20 mM Tris, and 20% methanol. The membranes were blocked and incubated with specific antibodies followed by incubation with horseradish peroxidase-conjugated second antibody, and immunoreactive bands were visualized by the enhanced chemiluminescence (ECL) detection system.
Binding Assays for Pak1 and Raf-1-For endogenous proteins, 1 mg of HEK293T cell extracts was immunoprecipitated overnight with 2 g of anti-Pak1 antibody preimmobilized to protein A/G-agarose beads in the presence of 2 g of Pak blocking peptide if necessary and washed five times with lysis buffer. The immunoprecipitates were resolved by SDS-PAGE (8%) using the Bio-Rad minigel system (1-mm thickness) and transferred to polyvinylidene difluoride membranes at 100 mA for 1 h. The membranes were then blotted overnight with Raf-1 E10 antibody (1 g/ml) in the presence or absence of 1 g/ml of Raf blocking peptide, followed by incubation with horseradish peroxidase-conjugated anti-mouse IgG antibody and developed by chemiluminescent method. Reciprocal immunoprecipitation and Western blot were performed in the same way.
For in vitro binding, Pak1 was expressed in HEK293T cells, purified with GSH beads, and incubated with purified baculovirally expressed recombinant Raf-1 at 4°C for 1 h. The unbound Raf was then washed out, and the retained Raf was blotted with anti-Raf (C12) antibody.
Pak Kinase Assays-Recombinant GST-Pak1 (full-length) and the carboxyl kinase domain were prepared as described above. Raf-1 tagged by GST at the amino terminus and six histidines at the carboxyl terminus was expressed in JM 109 cells and purified by sequentially passing GSH and Ni 2ϩ NTA-agarose columns (Qiagen). Phosphorylation of Raf was conducted by incubation of GST-Pak1 recombinant proteins (full-length or the carboxyl-terminal kinase domain) with Raf-1 in the kinase buffer containing 0.1 mM ATP and analyzed by immunoblotting with anti-phospho-Ser 338 antibody.
RESULTS

Pak1
Associates with Raf-1-Considerable evidence has demonstrated that Pak links Ras and Rac signaling avenues by phosphorylating Raf and MEK1 (21) (22) (23) (24) (25) (26) (27) (28) . To understand the mechanism by which Pak participates in regulation of Raf, the present study attempted to investigate the structural basis of Raf phosphorylation by Pak by examining whether there is a physical association between these two proteins. In the first study, endogenous Pak1 was immunoprecipitated from HEK293T cells, and co-purification of Raf-1 was examined by an anti-Raf-1 blot. As shown in Fig. 1A , Raf specifically bound to Pak1 (lane 1), as the Raf signal was diminished by adding specific peptides used for production of antibodies, either the Pak1 peptide during immunoprecipitation (lane 2) or the Raf peptide during immunoblotting of the associated Raf-1 (lane 3). Conversely, Pak1 was also found in the Raf immunoprecipitates (data not shown). In the second experiment (Fig. 1B) , Pak1 was overexpressed in HEK293T cells as a GST fusion protein and purified with glutathione-Sepharose beads. When the precipitates were subjected to Western blot, endogenous Raf was found in the Pak1 precipitates. In contrast, MEKK1, which is parallel to Raf-1 in a different MAPK signaling cascade, was not detected.
Next, we expressed both recombinant Pak and Raf and assessed the strength of association. In this experiment, GST-Pak1 was transiently expressed with Myc-Raf-1, and the recombinant proteins were purified with GSH beads or by immunoprecipitation and visualized by reciprocal blotting with antibodies against Myc or GST. Fig. 2A shows that the association of Pak with Raf increased with increasing doses of Pak1 cDNA. Fig. 2B reveals strong interaction between Pak and Raf-1, which withstood high salt washing.
To determine whether Pak1 directly associates with Raf, an in vitro binding assay was conducted. Thus, GST-Pak1 was expressed in HEK293T cells, precipitated with GSH beads, and incubated with baculoviral expressed recombinant Raf-1. The association was then assessed with anti-Raf-1 blot. As shown in Fig. 2C , some endogenous Raf copurified with GST-Pak1, and the signal was increased about twice as much by the addition of recombinant Raf-1. The affinity appeared to be low, yet specific, since under the same conditions it was obviously lower than that of 14-3-3, a well known binding partner, and none bound GST. The low affinity of binding may reflect nature of the kinase-substrate relationship and could also be attributed to their inactive conformations, as both Raf and Pak were inactive wild type in this assay. Therefore, all of these results demonstrate that Pak1 directly associates with Raf-1.
Active Pak Preferentially Associates with Raf-1-The crystal structure of Pak suggests that inactive Pak folds into a closed structure through the interaction between the autoinhibitory domain and the catalytic domain (30) . Active Rac or Cdc42 binds to Pak PBD, which overlaps the autoinhibitory domain, leading to derepression of the catalytic domain and changes in conformation so that Pak is available for its substrates. Hence, it is possible that active Pak has stronger interaction with Raf-1 than inactive Pak. To test this, Myc-Pak1 was co-transfected with GST-Raf-1 into HEK293T cells, and the cells were treated with either TPA or nocodazole. As shown in Fig. 3A , the recovery of Pak1 by Raf-1 was greatly stimulated by both agents. Additionally, when Pak1 and Raf-1 were co-expressed in the presence of an active mutant of Rac (V12), the association was also notably enhanced. A similar result was obtained in an experiment with co-expression of a constitutively active mutant of Ras (V12 KiRas) in which Raf/Ras interaction was not apparently altered by Pak1 (Fig. 3B) . Thus, these results indicate that the interaction between Pak1 and Raf-1 depends on their active conformations.
To further evaluate the preference of active Pak1 in binding to Raf-1, we employed Pak1 mutants, active or kinase-deficient, as compared with the wild type Pak1. In the first set of assays, GST-Pak1 (wild type, active mutant (T423E), or kinasedead mutant (K299A)) was co-expressed with or without MycRaf-1. When the GST-Pak1 complex was pulled down by GSH beads and blotted with anti-Raf antibody, the active mutant of Pak exhibited a binding to Raf-1 greater than that of the wild type, whereas the binding was barely detectable with the kinase-dead mutant. The same result was obtained with immunoprecipitation of endogenous Raf when single transfection of Pak variants, active or kinase-dead mutant, was performed. As shown in Fig. 4B , the strongest binding was observed with the active mutant of Pak1, with the wild type showing some binding and the kinase-dead mutant showing no binding. To further ascertain that the binding is specific, another version of Raf tagged by the FLAG epitope was used along with Myc-tagged Pak1, and the recombinant proteins were reciprocally immunoprecipitated and blotted. The results revealed that wild type Pak1 bound to Raf-1, whereas the kinase-dead mutant had no binding (middle part) or remarkably low binding (upper part) (Fig. 4C) . Collectively, these data demonstrate that the active conformation of Pak is important for binding to its substrate Raf-1.
Raf Binding Site Is Located in the Carboxyl Kinase Domain of Pak1- Fig. 5A depicts the structure of Pak1. To determine where the Raf binding domain resides on Pak1, we initially engineered constructs encoding the amino-terminal regulatory region (⌬C, aa 1-247) and the carboxyl-terminal kinase domain (⌬N, aa 248 -545) and expressed them in HEK293T cells. We noticed that although the carboxyl terminus contains 51 more amino acids than the amino terminus, the migration of the amino terminus on SDS-PAGE appeared to be slower than we predicted (Fig. 5B) . This could be due to differences in structure (e.g. there are four proline-rich domains in the amino terminus) or post-translational modification such as phosphorylation. When full-length Pak, the amino-terminal portion and the carboxyl-terminal kinase domain of Pak were each co-expressed with GST-Raf, both full-length Pak1 and the kinase domain of Pak1 bound to GST-Raf, and the binding was again intensified by TPA treatment of cells, whereas the amino terminus did not show any detectable binding. Thus, the result demonstrates that the Raf binding site is encompassed within the kinase domain of Pak1.
To define the Raf binding domain further, a series of truncations of the kinase domain were made by polymerase chain reaction as indicated in Fig. 6A . The PCR products were inserted into pEBG plasmid, as done with the wild type Pak1. Fig. 6B shows that the full-length Pak1 kinase domain (⌬N, aa 248 -545), P1 (aa 347-545), and P2 (aa 464 -545) each bound to Raf-1. Next, we tested another set of mutations in which deletions were made from the carboxyl terminus. The result showed that the Raf binding site was contained within the sequence (residues 347-545) that bears a conserved substrate binding site (VIb-IX, aa 387-459) (Fig. 6C) (30, 31) . Interestingly, the Raf binding site apparently extended over the subdomains VI-IX, as the fragment 464 -545 also bound Raf. The apparent magnitude of Pak1 deletion mutants binding to Raf was summarized in Fig. 6A , which was based on calculation of the signal ratio of the bound Raf to Pak variants used for the binding assay. Since each mutant showed different stability, it was very difficult to manipulate them to the same expression level. Nonetheless, the intact kinase domain showed the greatest binding to Raf-1. Regulation of Raf-1 by the Kinase Domain of Pak1-Since the active Pak1 bound to Raf more avidly than did the inactive Pak1, we were curious to explore whether such strong association would lead to an increase in phosphorylation of Raf-1. Thus, we first compared the ability of the full-length and the kinase domain of Pak1 to phosphorylate Raf-1 in vitro. Wild type and kinase domain of GST-Pak1 isolated from 293T cells were incubated with bacterially expressed Raf-1 in the presence of ATP. Phosphorylation of Raf was assessed by antiphospho-Ser 338 blot (Fig. 7A) . Whereas phosphorylation of Raf Ser 338 by the Pak kinase domain was detected, the full-length Pak showed almost no effect. The failure to see phosphorylation of Raf-1 by the full-length Pak1 might be accounted for by several factors; for instance, the bacterially recombinant Raf-1 lacks such important cofactors as Ras, 14-3-3, and heat shock proteins, all of which are required for maintaining the opened conformation of Raf. Thus, full-length Pak with low affinity is not able to attack Raf as efficiently as the amino-terminally truncated Pak. Another comparison was made by introducing Pak variants into cells with Raf-1. Results in Fig. 7B revealed that the ability of the carboxyl kinase domain to phosphorylate Raf Ser 338 was greater than that of the full-length Pak1, in agreement with the binding profile of these two versions of Pak1 to Raf. Furthermore, overexpression of the Pak1 kinase domain significantly enhanced MAPK activation by Raf-1 as judged by anti-phospho-MAPK blot, whereas no such effect was observed with the full-length Pak1 (Fig. 7C) . Thus, the results suggest that the ability of Pak1 to phosphorylate Raf Ser 338 and to induce Raf activation is dependent on the strength of its binding to Raf.
Inhibitory Role of the Amino Terminus of Raf in Raf/Pak
Interaction-We compared the ability of full-length and carboxyl kinase domain of Raf to bind to Pak1. To do so, Raf constructs encoding GST fusion proteins of the Raf full-length and carboxyl-terminal domain (BXBRaf) were each co-transfected into COS7 cells with Myc-Pak1. An anti-Myc immunoblot after GST purification showed that the binding of the Raf kinase domain to Pak1 was much greater than that of the full-length Raf-1, while the expression of each protein was manipulated to a comparable level (Fig. 8) . Thus, the result suggests that the amino-terminal domain of Raf inhibits its binding to Pak.
DISCUSSION
Active RasGTP binds to the Ras binding domain and zinc finger motif at the amino terminus of Raf. This binding induces a conformational change of Raf-1, which yields an opened structure suitable for phosphorylation by membrane-associated kinases. In the past, tremendous effort has been made to identify phosphorylation sites necessary for Raf activation and the kinases that phosphorylate these sites. In the junction region between the amino terminus and carboxyl-terminal catalytic domain, there are Ser 338 and Tyr 341 , whose phosphorylation has attracted a great deal of attention (24 -28, 32-36 and Raf-1. The results revealed that the strength of the association depends on the active conformation of Pak1. They also demonstrated that the Raf binding site is located in the carboxyl terminus of the Pak kinase domain. Thus, our study suggests that Pak is a physiological kinase that phosphorylates Raf Ser 338 necessary for Raf-1 activation. Recent studies have demonstrated that Thr 423 in the activation loop of Pak1, also conserved in other isoforms of the Pak family, is autophosphorylated (16, 17) or transphosphorylated by PDK1 (37) . The phosphorylation of this site is crucial for the activity of Pak1 toward substrates (17) . In addition, it has been documented that autophosphorylation of residues in the KI region (Ser 145 and Ser 150 on Pak1) is necessary for the activation of Pak (17) . Collectively, these studies suggest that phosphorylation of these sites disrupts an inhibitory interaction between KI and the catalytic domain of Pak. The present study investigates whether activation of Pak leads to an increase in its interaction with the substrate Raf-1. We have shown here that the association between Pak and Raf-1 is stimulated by nocodazole, which is most likely dependent on Rac or Cdc42, since we previously demonstrated that nocodazole induces sequential activation of Pak and Raf-1 in a Rac/Cdc42-dependent fashion (27) . We also found that the binding is up-regulated by TPA. It has been shown that TPA activates Raf-1 through both a Ras-dependent mechanism (38) and direct phosphorylation of the Raf catalytic domain by protein kinase C (39). Akasaki et al. (40) have reported that phorbol 12-myristate 13-acetate causes an activation of Rac2 as reflected by increased binding to GTP and to Pak PBD. Thus, we propose that the activated Ras could signal to Rac, which in turn activates Pak and increases Pak binding to Raf. Consistent with this is our finding that binding between Pak and Raf is augmented by overexpression of active mutants of Rac and Ras. The requirement of the active conformation of Pak for the binding to Raf is further corroborated by our findings that the T423E mutant of Pak1 and amino-terminally truncated Pak1 bind to Raf-1 more potently than does the full-length wild type Pak1, whereas binding of the kinase-dead mutant (K299A) is only minimally detectable. Moreover, the binding strength of Pak1 mutants to Raf-1 is closely correlated with their ability to phosphorylate Raf Ser 338 and activate Raf/MAPK. Thus, the present study indicates that binding of Pak1 to Raf-1 is secondary to disruption of the interaction between the amino-terminal inhibitory region and the catalytic domain of Pak1.
Like other kinases (31), the catalytic domain of Pak1 is structurally composed of two lobes, a small lobe (N lobe) and a large lobe (C lobe). The small lobe mainly involves binding to ATP, while the large lobe provides a binding site for peptide substrates. A phosphotransfer reaction is achieved by coordination between the two lobes and their interaction with substrates (ATP and protein substrates). To further map the binding site, we carefully made truncation deletions of the catalytic domain so that the functional segments (i.e. ␤-strands and ␣-helices) were not interrupted. Our data showed that Raf-1 is not able to bind to the Pak P3 mutant (aa 248 -346), which presumably assembles into the N lobe (30) . The results further FIG. 4 . Active Pak1 strongly binds to Raf-1. A, GST-Pak1 variants, wild type (WT), active mutant (CA), and kinase-dead mutant (KD), were each transfected into HEK293T cells with Myc-tagged Raf-1. The recombinant Pak proteins were purified with GSH-Sepharose beads, and the association was examined as in Fig. 2A . B, Pak variants as in A, tagged by the Myc epitope, were each expressed alone. Endogenous Raf-1 was immunoprecipitated and blotted with anti-Myc antibody. C, cDNAs encoding FLAG-Raf-1 and Myc-Pak1 variants (WT and KD) were co-expressed. The association was examined by reciprocal immunoprecipitation and immunoblotting as indicated. Cell lysates were loaded for Western blot controls.
indicated that Raf-1 associates with two sites within the C lobe of Pak1. The first site is contained within residues 347-463. According to alignment with conserved kinase domains, the region of aa 347-463 includes subdomains between VI and IX, which is suggested to bear the peptide substrate binding domain.
Interestingly, we also found that Raf-1 binds to a more carboxyl-terminal fragment of Pak1 consisting of residues 464 -545. This sequence is less conserved among kinases, and its function is not well defined. Crystal structure studies suggest that the KI segment occupies the cleft between the N lobe and C lobe through interaction with the catalytic loop and activation loop, maintaining the enzyme's inactive conformation. The inhibitory role of the KI is then reinforced by another interaction between a helix (␣-G) within the C lobe and the IS domain (Fig. 9) . The ␣-G is located just within the sequence that contains the second binding site for Raf-1 shown in this study. Hence, it is conceivable that active GTP-Cdc42 or Rac binds to PBD, which changes the conformation of the IS domain and destabilizes the interaction between the IS and ␣-G, thereby intervening the KI-mediated interaction. This structural transition allows Pak to undergo autophosphorylation to secure an active conformation. It also permits the segment containing ␣-G to bring Raf close to Pak such that the phosphorylation motif (sequence around Ser 338 ) of Raf can be trapped into the substrate recognition domain (VI-IX) of Pak, resulting in phos- were each co-expressed with GST-Raf-1 or GST. The complexes were purified with GSH-Sepharose beads after cell treatment with TPA as described in Fig. 3A . Immunoblotting of Myc-Pak, GST-Raf, and GST proteins was performed after or before purification. These results were reproduced twice.
phorylation of Raf Ser 338 (Fig. 9 ). This model should be able to be tested by mutation of Pak residues involved in the interface interaction between the IS and ␣G.
Another interesting observation is that binding of the Raf catalytic domain to Pak1 is more vigorous than that of the full-length Raf-1, suggesting that the amino-terminal regula- tory region of Raf-1 blocks Raf interaction with its upstream kinase such as Pak. Since some investigators observe phosphorylation of Raf Ser 338 by Pak while others do not, our findings may serve to resolve the argument on whether Pak is a Ser 338 kinase for Raf activation. Thus, in light of our results and those published by others, we propose a model for Pak participation in V12Ras-induced activation of Raf-1. A signal from Ras-GTP bifurcates to both Raf and Rac. On the one hand, binding of Ras-GTP to the amino terminus alleviates the inhibition of the Raf-1 catalytic domain imposed by such amino-terminal sequences as the zinc finger domain (27, (41) (42) (43) . As a result, Raf becomes accessible to upstream kinases such as Pak. On the other hand, active Ras causes Pak activation by binding to GTP-Rac and subsequent conformational changes in Pak. The meeting of these two structurally opened kinases results in phosphorylation of Raf-1. This hypothesis is currently under investigation.
We wish to reiterate the following two points: first, phosphorylation of Raf Ser 338 is a necessary step but not the final step in Raf activation (27, 29, 36) , and second, it appears that multiple Raf Ser 338 kinases including Pak exist for Raf activation (29, 36) . Previous studies have demonstrated that mutation of Raf Ser 338 to Ala abrogates Raf activation, while mutation to Glu or Asp causes a slight but not full activation of Raf-1 (33) . On several occasions, co-expression of active Rac, Cdc42, or Pak does not activate Raf (23, 29) . When these proteins are expressed at high levels, Raf-1 can be moderately activated (25, 27, 44) . However, they can synergize with such agents as growth factors, TPA and nocodazole, leading to a robust activation of Raf-1. The dominant interfering mutants of Pak and its surrogates can inhibit Raf activation under some but not all circumstances. For example, they appear to inhibit Raf activation by integrin (26) and nocodazole (27) but not by epidermal growth factor (23, 27, 29) .
Recent studies suggest that Ras may recruit distinct kinases to phosphorylate Raf Ser 338 . Mutagenesis studies have delineated residues critical for activation of Raf and phosphatidylinositol 3-kinase/Rac (12, 45 ). An early study by Joneson et al. (12) reported that mutation of the residue Thr 35 to Ser diminished the ability of Ha-Ras (V12) to activate phosphatidylinositol 3-kinase and Rac, without an effect on Raf-1 activation. By contrast, Li et al. (28) showed that the K-Ras (T35S) mutant bound Raf normally but failed to activate Raf unless the latter was co-expressed with Rac/Cdc42/Pak. These discrepant results may be ascribed to different features of the Ras isoforms. Indeed, one report showed that K-Ras stimulated Rac and Pak association twice as much as Ha-Ras (46). Taken together, these studies suggest that Ki-Ras-induced activation of Raf is GST-Paks, full-length and kinase domain, were prepared from transfected HEK293T cells, and GST-Raf-1 was purified from E. coli. The phosphorylation assay was carried out as described under "Experimental Procedures" and assessed by anti-phospho-Ser 338 blot. B, GST-Raf-1 was co-expressed with full-length Pak1 or the amino terminus or kinase domain of Pak1. The complexes were visualized by immunoblotting with anti-Myc antibody after GSH purification (upper part). Equal recovery of Raf-1 was assessed with anti-GST antibody, and phosphorylation of Raf Ser 338 was simultaneously examined as well (middle two parts). The bottom two parts show levels of recombinant Pak and Raf in cell lysates. C, expression of Myc-Paks and GST-Raf-1 were examined by immunoblotting as indicated, and MAPK activation was assessed by sequential blottings with anti-phospho-MAPK/ Erk and MAPK/Erk antibodies. mediated by Pak, while Ha-Ras may employ another kinase to phosphorylate Ser 338 . Since Ha-Ras is a more potent activator of phosphatidylinositol 3-kinase than K-Ras (47), the question then arises with regard to how Raf-1 is activated by Ha-Ras in a phosphatidylinositol 3-kinase/Rac/Pak-independent fashion. A second question is what contributes to the difference between these two Ras proteins. A possible explanation is their different localization at the plasma membrane. The first 86 amino acids of Ras proteins harboring the effector-binding domain are completely identical, while the carboxyl termini consisting of residues 166 -185 are highly divergent. The carboxyl terminus of Ha-Ras undergoes farnesylation, proteolytic cleavage, caroxylmethylation, and the subsequent palmitoylation. This processing allows Ha-Ras to translocate to the caveolin-enriched plasma membrane microdomain (48) , where a different Raf Ser 338 kinase may reside. By contrast, K-Ras is not palmitoylated but instead contains a polybasic sequence that directs its association with the noncaveolin region of the plasma membrane (49) . The present study employs K-Ras (V12), which may cause conformational changes of both Pak1 and Raf-1, resulting in the increased binding as discussed above.
In essence, our study presents convincing evidence that Pak1 associates with Raf-1. The strength of such association is correlated with the activation state of Pak. Accordingly, the Pak1 carboxyl-terminal kinase domain manifests a greater ability than the full-length Pak1 to bind to Raf and phosphorylate Ser 338 . Our data also suggest that the opened structure of Raf-1 is more favorable for this interaction. Furthermore, the Raf binding site is localized to the carboxyl terminus of the Pak catalytic domain. Overall, the present study strongly indicates that Pak serves as a physiological kinase phosphorylating Raf Ser 338 . The results provide new insight into the mechanism by which Raf is activated. They also provide a framework to study the structural basis for Pak to phosphorylate other substrates. Indeed, Pak2 has recently been shown to interact with c-Abl (50) . Interestingly, activation of Pak2 by an active mutant of Cdc42 up-regulates c-Abl activity. By contrast, cotransfection of c-Abl and Pak2 leads to tyrosine phosphorylation of and a decrease in activity of the latter. Whether their interaction is similar to that between Raf and Pak is worth examining.
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